6533b7dafe1ef96bd126ed0f

RESEARCH PRODUCT

Transarterial Chemoembolization Before Liver Transplantation in 60 Patients With Hepatocellular Carcinoma

Michael HeiseM. Hoppe-lotichiusM. SchuchmannM. PittonF. BittingerG. OttoC. MoenchSascha Herber

subject

medicine.medical_specialtyCarcinoma HepatocellularTime Factorsmedicine.medical_treatmentLiver transplantationMilan criteriaGastroenterologyDisease-Free SurvivalRecurrenceInternal medicinePreoperative CaremedicineHumansEmbolizationChemoembolization TherapeuticTransplantationbusiness.industryPatient SelectionLiver Neoplasmsmedicine.diseaseSurvival AnalysisLiver TransplantationSurgeryTransplantationTumor progressionHepatocellular carcinomaSurgerybusinessLiver cancerProgressive disease

description

Tumor recurrence is a major problem after orthotopic liver transplantation (OLT) in patients with hepatocellular carcinoma (HCC). In 60 patients OLT was performed for HCC after pretreatment by repeated transarterial chemoembolization (TACE). Forty-four recipients exceeded the Milan criteria. Recurrence-free 5-year survival was 65.2% and 5-year freedom from recurrence was 73.2%. During the waiting time, 14 patients experienced minimal change, which did not fulfill the definition of tumor progression according to official oncological criteria. Five-year freedom from recurrence among patients with stable compared with progressive disease was 93.3% versus 28.1%, respectively (P = .0001). A strict TACE pretreatment protocol may select patients with obviously biologically less aggressive tumors, who are suitable for OLT even if the HCC exceeds the commonly accepted listing criteria.

yearjournalcountryeditionlanguage
2007-03-01Transplantation Proceedings
https://doi.org/10.1016/j.transproceed.2006.12.007